According to our data, although KRAS mutations were the dominant form of RAS/RAF pathway mutations in MLH1-unmethylated CIMP-H CRC, a small portion of MLH1-unmethylated CIMP-H CRCs displayed BRAF mutations (8% to 13%; Tables 2, 3). This evidence concerns the gene KRAS and colorectal carcinoma.